• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 8

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Dr Ros Watts – Building Communities and Connection

The Psychedelic News Feed: October 27 – November 02, 2025

Compass Pathways Accelerates Psilocybin Launch Timeline by 9-12 Months

CLOSING RECEPTION Travis Gillan’s Revelator

Pα+ Psychedelic Bulletin #212: Delix Posts Early Efficacy Signal; NRx Wants FDA to Ban Competitors’ Ketamine; Cybin Raises $175M

Alan Davis – Psychedelic Research and Patient Safety at Ohio State...

Chad Charles – Integrating 5-MeO-DMT: Therapy, Harm Reduction, and Best Practices

Germany Establishes EU’s First Psilocybin Compassionate Access Program

Chad Charles – Integrating 5-MeO-DMT: Therapy, Harm Reduction, and Best Practices

Dispatch: The Neurobiology of Psychedelics Gordon Research Conference — Circuitry, Consciousness,...

William Leonard Pickard interviews Bryan Hubbard about the new policy frontier...

Pα+ Psychedelic Bulletin #204: FDA Keeps GH Research’s 5-MeO-DMT on Ice;...

June 2025 Psychedelic Patent Update

Alan Davis – Psychedelic Research and Patient Safety at Ohio State...

Dispatch: The Neurobiology of Psychedelics Gordon Research Conference — Plasticity, Psychotherapy,...

1...789...301Page 8 of 301

EDITOR PICKS

Dr Ros Watts – Building Communities and Connection

The Psychedelic News Feed: October 27 – November 02, 2025

Compass Pathways Accelerates Psilocybin Launch Timeline by 9-12 Months

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©